GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (NAS:XGN) » Definitions » Debt-to-Equity

Exagen (Exagen) Debt-to-Equity : 1.05 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Exagen Debt-to-Equity?

Exagen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.73 Mil. Exagen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $21.99 Mil. Exagen's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $22.69 Mil. Exagen's debt to equity for the quarter that ended in Dec. 2023 was 1.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Exagen's Debt-to-Equity or its related term are showing as below:

XGN' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.06   Med: 0.33   Max: 1.05
Current: 1.05

During the past 11 years, the highest Debt-to-Equity Ratio of Exagen was 1.05. The lowest was -4.06. And the median was 0.33.

XGN's Debt-to-Equity is ranked worse than
85.79% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs XGN: 1.05

Exagen Debt-to-Equity Historical Data

The historical data trend for Exagen's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exagen Debt-to-Equity Chart

Exagen Annual Data
Trend Dec13 Dec14 Dec15 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.65 0.33 0.83 1.05

Exagen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.98 0.79 0.90 1.05

Competitive Comparison of Exagen's Debt-to-Equity

For the Diagnostics & Research subindustry, Exagen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exagen's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exagen's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Exagen's Debt-to-Equity falls into.



Exagen Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Exagen's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Exagen's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exagen  (NAS:XGN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Exagen Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Exagen's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Exagen (Exagen) Business Description

Traded in Other Exchanges
Address
1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Executives
John Aballi director, officer: President and CEO C/O DECIPHER BIOSCIENCES, INC., 6925 LUSK BLVD, SUITE 200, SAN DIEGO CA 92121
Paul Kim director 4399 SANTA ANITA AVE, EL MONTE CA 91731
Tullis Growth Fund Ii, L.p. 10 percent owner 11770 US HWY 1, STE 503, PALM BEACH GARDENS FL 33408
Kamal Adawi officer: Chief Financial Officer C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92131
Mark Hazeltine officer: Chief Operating Officer C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Wendy S. Johnson director 800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
Tullis James L L director, 10 percent owner 100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Ana Hooker director 441 CHARMANY DRIVE, MADISON WI 53719
Frank Stokes director C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Hunt Holdings Limited Partnership 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Nmsic Co-investment Fund, L.p. 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Debra Zack officer: Chief Medical Officer C/O EXAGEN, INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
H.i.g. Bio-exagen, L.p. 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Thierry Dervieux officer: Chief Scientific Officer C/O EXAGEN DIAGNOSTICS, INC., 1261 LIBERTY WAY, VISTA CA 92081
Nmsic Focused Llc 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081

Exagen (Exagen) Headlines

From GuruFocus

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

By Value_Insider Value_Insider 11-08-2022

Exagen Announces Campaign for Lupus Awareness Month

By sperokesalga sperokesalga 05-01-2023

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

By Stock market mentor Stock market mentor 01-23-2023

Is Exagen Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 12-11-2022

Top 5 2nd Quarter Trades of HighTower Trust Services, LTA

By GuruFocus Research GuruFocus Editor 07-22-2022